-
Mashup Score: 0Novel autoantibodies help diagnose anti-SSA antibody negative Sjögren disease and predict abnormal labial salivary gland pathology - 2 hour(s) ago
Objectives Sjögren disease (SjD) diagnosis often requires either positive anti-SSA antibodies or a labial salivary gland biopsy with a positive focus score (FS). One-third of patients with SjD lack anti-SSA antibodies (SSA−), requiring a positive FS for diagnosis. Our objective was to identify novel autoantibodies to diagnose ‘seronegative’ SjD. Methods IgG binding to a high-density whole human peptidome array was quantified using sera from SSA− SjD cases and matched non-autoimmune controls. We identified the highest bound peptides using empirical Bayesian statistical filters, which we confirmed in an independent cohort comprising SSA− SjD (n=76), sicca-controls without autoimmunity (n=75) and autoimmune-feature controls (SjD features but not meeting SjD criteria; n=41). In this external validation, we used non-parametric methods for binding abundance and controlled false discovery rate in group comparisons. For predictive modelling, we used logistic regression, model selection methods
Source: ard.bmj.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 28Systematic literature review to inform the EULAR recommendations for the use of imaging in crystal-induced arthropathies in clinical practice - 13 hour(s) ago
Objective To summarise current data regarding the use of imaging in crystal-induced arthropathies (CiAs) informing a European Alliance of Associations for Rheumatology task force. Methods We performed four systematic searches in Embase, Medline and Central on imaging for diagnosis, monitoring, prediction of disease severity/treatment response, guiding procedures and patient education in gout, calcium pyrophosphate dihydrate deposition (CPPD) and basic calcium phosphate deposition (BCPD). Records were screened, manuscripts reviewed and data of the included studies extracted. The risk of bias was assessed by validated instruments. Results For gout, 88 studies were included. Diagnostic studies reported good to excellent sensitivity and specificity of dual-energy CT (DECT) and ultrasound (US), high specificity and lower sensitivity for conventional radiographs (CR) and CT. Longitudinal studies demonstrated sensitivity to change with regard to crystal deposition by US and DECT and inflammat
Source: ard.bmj.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 49Philip S Hench and the discovery of cortisone - 1 day(s) ago
This year, 2024, marks the 75th anniversary of the presentation of a landmark discovery in the biology and management of rheumatoid arthritis. On 13 April 1949, Philip S Hench (1896–1965) gave a lecture to an overfilled Mayo Clinic staff meeting in Rochester, Minnesota, USA, on observations of ‘The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis’.1 The sensational results were soon known worldwide, making further headlines on 31 May 1949 when Hench presented a more complete report and motion pictures of treated patients at the Seventh International Congress of Rheumatic Diseases held at the Waldorf Astoria Hotel in New York City (figure 1). As reported by physicians present at the lecture, excitement about an effective treatment, and possibly even cure of one of humankind’s most poorly understood and heretofore untreatable disease was greeted by the hundreds of attendees wit
Source: ard.bmj.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 48Inflammatory tissue priming: novel insights and therapeutic opportunities for inflammatory rheumatic diseases - 4 day(s) ago
Due to optimised treatment strategies and the availability of new therapies during the last decades, formerly devastating chronic inflammatory diseases such as rheumatoid arthritis or systemic sclerosis (SSc) have become less menacing. However, in many patients, even state-of-the-art treatment cannot induce remission. Moreover, the risk for flares strongly increases once anti-inflammatory therapy is tapered or withdrawn, suggesting that underlying pathological processes remain active even in the absence of overt inflammation. It has become evident that tissues have the ability to remember past encounters with pathogens, wounds and other irritants, and to react more strongly and/or persistently to the next occurrence. This priming of the tissue bears a paramount role in defence from microbes, but on the other hand drives inflammatory pathologies (the Dr Jekyll and Mr Hyde aspect of tissue adaptation). Emerging evidence suggests that long-lived tissue-resident cells, such as fibroblasts,
Source: ard.bmj.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 23Disease flares with baricitinib dose reductions and development of flare criteria in patients with CANDLE/PRAAS - 5 day(s) ago
Objectives Patients with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS) respond to the janus kinase inhibitor 1/2 inhibition with baricitinib at exposures higher than in rheumatoid arthritis. Baricitinib dose reductions to minimise exposure triggered disease flares which we used to develop ‘flare criteria’. Methods Of 10 patients with CANDLE/PRAAS treated with baricitinib in an open-label expanded-access programme, baricitinib doses were reduced 14 times in 9 patients between April 2014 and December 2019. Retrospective data analysis of daily diary scores and laboratory markers collected before and after the dose reductions were used to develop ‘clinical’ and ‘subclinical’ flare criteria. Disease flare rates were compared among patients with 25% dose reductions and during study visits when patients received recommended ‘optimized’ baricitinib doses (high-dose visits) versus low
Source: ard.bmj.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 27
Emerging evidence points to the involvement of periodontal disease (PD) in the pathogenesis of rheumatoid arthritis (RA), especially in anti-citrullinated protein antibodies (ACPA)-positive RA. The bacteria Porphyromonas gingivalis , involved in oral mucosal inflammation and PD, can citrullinate proteins via prokaryotic peptidylarginine deiminase.1 Systemic translocation of oral bacteria has been found in RA-patients with PD. These bacterial translocations have been implicated in the generation of anti-modified protein antibodies (AMPAs) as ACPA can also recognise modified bacterial proteins.2 Nevertheless, the ‘cause-consequence’ relation between PD and RA remains debatable as PD may be a risk factor (PD→RA; scenario 1; figure 1A) but also a consequence of RA (RA→PD; scenario 2).3 Additionally, the relation PD→RA may be confounded by related factors (eg, body mass index (BMI), smoking or other factors related to socioeconomic status (SES); scenario 3). Increased prevalence of periodon
Source: ard.bmj.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 104
Objectives In the complex panorama of autoimmune diseases, the characterisation of pivotal contributing autoantibodies that are involved in disease progression remains challenging. This study aimed to employ a global antibody profiling strategy to identify novel antibodies and investigate their association with systemic sclerosis (SSc). Methods We implemented this strategy by conducting immunoprecipitation (IP) following on-bead digestion with the sera of patients with SSc or healthy donors, using antigen pools derived from cell lysates. The enriched antigen-antibody complex was proceeded with mass spectrometry (MS)-based quantitative proteomics and over-represented by bioinformatics analysis. The candidate antibodies were then orthogonally validated in two independent groups of patients with SSc. Mice were immunised with the target antigen, which was subsequently evaluated by histological examination and RNA sequencing. Results The IP-MS analysis, followed by validation in patients wi
Source: ard.bmj.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 49
Giant cell arteritis (GCA), the most common systemic vasculitis, is characterised by aberrant interactions between infiltrating and resident cells of the vessel wall. Ageing and breach of tolerance are prerequisites for GCA development, resulting in dendritic and T-cell dysfunction. Inflammatory cytokines polarise T-cells, activate resident macrophages and synergistically enhance vascular inflammation, providing a loop of autoreactivity. These events originate in the adventitia, commonly regarded as the biological epicentre of the vessel wall, with additional recruitment of cells that infiltrate and migrate towards the intima. Thus, GCA-vessels exhibit infiltrates across the vascular layers, with various cytokines and growth factors amplifying the pathogenic process. These events activate ineffective repair mechanisms, where dysfunctional vascular smooth muscle cells and fibroblasts phenotypically shift along their lineage and colonise the intima. While high-dose glucocorticoids broadl
Source: ard.bmj.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 26Managing Systemic Lupus Erythematosus: the latest EULAR recommendations | ARD Podcast - 10 day(s) ago
This podcast brings you the 2023 update on the EULAR recommendations for the management of systemic lupus erythematosus (SLE). ARD’s Social Media Advisor, Professor Laura Andreoli, speaks to Professors Antonios Fanouriakis and Dimitrios Boumpas, both from the “Attikon” University Hospital, National and Kapodistrian University of Athens, Greece, two of the authors of the recommendations paper. Read it on the ARD website: https://ard.bmj.com/content/83/1/15. Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page – https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059 .
Source: ardbmj.podbean.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 22
Introduction AA amyloidosis (AA) can be the consequence of any chronic inflammatory disease. AA is associated with chronic inflammatory diseases (cid+AA), autoinflammatory syndromes (auto+AA) or AA of unknown origin or idiopathic AA (idio+AA). The major organ manifestation is renal AA that can progress to end-stage renal disease (ESRD) and multiple organ failure. Materials and methods This study is a monocentric retrospective analysis of the renal outcome and survival of patients with cid+AA (n=34), auto+AA (n=24) and idio+AA (n=25) who were treated with cytokine-inhibiting biological disease-modifying antirheumatic drugs (bDMARDs). Results 83 patients with renal AA were identified and followed for a mean observational period of 4.82 years. C reactive protein (CRP), serum amyloid alpha and proteinuria were significantly reduced with bDMARD therapy. Progression to ESRD was prevented in 60% (cid+AA), 88% (auto+AA) and 81% (idio+AA) of patients. Tocilizumab was given to 34 patients with c
Source: ard.bmj.comCategories: General Medicine News, RheumatologyTweet
🔬 Breakthrough in Diagnosis of Sjögren's Disease?!? Researchers have identified novel autoantibodies that diagnose 'seronegative' cases and predict abnormal salivary gland pathology, enhancing both diagnosis and patient care🧪 🔍 https://t.co/VW06W9zMCI https://t.co/qaD4QvZJli